Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis

Microbiome precision editing: Using PEG as a selective fermentation initiator against methicillin‐resistant Staphylococcus aureus

“…CA-MRSA is reported as the most common cause of purulent skin and soft tissue infections in the US [39]. It is assessed that S. aureus accounts for 12 million outpatient visits and 292,000 hospitalizations of which 126,000 are due to MRSA annually in the US alone [38].…”

“…In contrast, probiotic treatments, which are relatively independent on patients’ health matters, have little or no interference with commensal microbes may complement antibiotics or PEG-DMA on the growth of various skin microbes have been not examined in this study, we believe that PEG-DMA will not systemically induce an imbalance of the human microbiome since it is applied locally onto a skin wound. Besides the function of PEG-DMA as a SFI, we believe that when PEG-DMA is used with antibiotics, it has potential to be an antibiotic adjuvant [39] to augment the fermentation activity of S. epidermidis and reduce the effective doses of antibiotics, decreasing the risk of generating resistant S. aureus and non-specific killing effect of antibiotics on skin commensals. Many bacteria can selectively use substrates from a mixture of different carbon sources via the regulation of carbon catabolite repression (CCR) [40].…”

Microbiome precision editing: Using PEG as a selective fermentation initiator against methicillin‐resistant Staphylococcus aureus

“…CA-MRSA is reported as the most common cause of purulent skin and soft tissue infections in the US [39]. It is assessed that S. aureus accounts for 12 million outpatient visits and 292,000 hospitalizations of which 126,000 are due to MRSA annually in the US alone [38].…”

“…In contrast, probiotic treatments, which are relatively independent on patients’ health matters, have little or no interference with commensal microbes may complement antibiotics or PEG-DMA on the growth of various skin microbes have been not examined in this study, we believe that PEG-DMA will not systemically induce an imbalance of the human microbiome since it is applied locally onto a skin wound. Besides the function of PEG-DMA as a SFI, we believe that when PEG-DMA is used with antibiotics, it has potential to be an antibiotic adjuvant [39] to augment the fermentation activity of S. epidermidis and reduce the effective doses of antibiotics, decreasing the risk of generating resistant S. aureus and non-specific killing effect of antibiotics on skin commensals. Many bacteria can selectively use substrates from a mixture of different carbon sources via the regulation of carbon catabolite repression (CCR) [40].…”

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis

“…In the context of infectious disease, adjuvants have been defined as ‘therapies that act by rendering the organism more susceptible to attack by antibiotics or the host immune system, by rendering the organism less virulent or killing it by other means’. 172 A number of approaches have been proposed as candidates for adjuvant therapy in NTM infection in CF, including interferon γ (IFNγ; or agents that promote IFNγ release) and vitamin D. Drug delivery vehicles, such as liposomes, may be considered adjuvants. Liposomes have been studied as a mode of delivering amikacin for infection with P. aeruginosa in CF, 173 and this approach is also being evaluated (clinicaltrials.gov/show/NCT01315236) for NTM.…”

Professor Pangloss and the Pangenome: Does Staphylococcus aureus Have the Best of All Possible Worlds?

“…Finally, the authors suggest that new antimicrobial agents might be designed to reduce the virulence of the organism without exerting selective pressure for resistance -such agents have been proposed as useful "antibiotic adjuvants" (17).…”

Microbiome precision editing: Using PEG as a selective fermentation initiator against methicillin‐resistant Staphylococcus aureus

“…CA-MRSA is reported as the most common cause of purulent skin and soft tissue infections in the US [39]. It is assessed that S. aureus accounts for 12 million outpatient visits and 292,000 hospitalizations of which 126,000 are due to MRSA annually in the US alone [38].…”

“…In contrast, probiotic treatments, which are relatively independent on patients’ health matters, have little or no interference with commensal microbes may complement antibiotics or PEG-DMA on the growth of various skin microbes have been not examined in this study, we believe that PEG-DMA will not systemically induce an imbalance of the human microbiome since it is applied locally onto a skin wound. Besides the function of PEG-DMA as a SFI, we believe that when PEG-DMA is used with antibiotics, it has potential to be an antibiotic adjuvant [39] to augment the fermentation activity of S. epidermidis and reduce the effective doses of antibiotics, decreasing the risk of generating resistant S. aureus and non-specific killing effect of antibiotics on skin commensals. Many bacteria can selectively use substrates from a mixture of different carbon sources via the regulation of carbon catabolite repression (CCR) [40].…”

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis

“…In the context of infectious disease, adjuvants have been defined as ‘therapies that act by rendering the organism more susceptible to attack by antibiotics or the host immune system, by rendering the organism less virulent or killing it by other means’. 172 A number of approaches have been proposed as candidates for adjuvant therapy in NTM infection in CF, including interferon γ (IFNγ; or agents that promote IFNγ release) and vitamin D. Drug delivery vehicles, such as liposomes, may be considered adjuvants. Liposomes have been studied as a mode of delivering amikacin for infection with P. aeruginosa in CF, 173 and this approach is also being evaluated (clinicaltrials.gov/show/NCT01315236) for NTM.…”

Professor Pangloss and the Pangenome: Does Staphylococcus aureus Have the Best of All Possible Worlds?

“…Finally, the authors suggest that new antimicrobial agents might be designed to reduce the virulence of the organism without exerting selective pressure for resistance -such agents have been proposed as useful "antibiotic adjuvants" (17).…”

Microbiome precision editing: Using PEG as a selective fermentation initiator against methicillin‐resistant Staphylococcus aureus

“…CA-MRSA is reported as the most common cause of purulent skin and soft tissue infections in the US [39]. It is assessed that S. aureus accounts for 12 million outpatient visits and 292,000 hospitalizations of which 126,000 are due to MRSA annually in the US alone [38].…”

“…In contrast, probiotic treatments, which are relatively independent on patients’ health matters, have little or no interference with commensal microbes may complement antibiotics or PEG-DMA on the growth of various skin microbes have been not examined in this study, we believe that PEG-DMA will not systemically induce an imbalance of the human microbiome since it is applied locally onto a skin wound. Besides the function of PEG-DMA as a SFI, we believe that when PEG-DMA is used with antibiotics, it has potential to be an antibiotic adjuvant [39] to augment the fermentation activity of S. epidermidis and reduce the effective doses of antibiotics, decreasing the risk of generating resistant S. aureus and non-specific killing effect of antibiotics on skin commensals. Many bacteria can selectively use substrates from a mixture of different carbon sources via the regulation of carbon catabolite repression (CCR) [40].…”

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis

“…In the context of infectious disease, adjuvants have been defined as ‘therapies that act by rendering the organism more susceptible to attack by antibiotics or the host immune system, by rendering the organism less virulent or killing it by other means’. 172 A number of approaches have been proposed as candidates for adjuvant therapy in NTM infection in CF, including interferon γ (IFNγ; or agents that promote IFNγ release) and vitamin D. Drug delivery vehicles, such as liposomes, may be considered adjuvants. Liposomes have been studied as a mode of delivering amikacin for infection with P. aeruginosa in CF, 173 and this approach is also being evaluated (clinicaltrials.gov/show/NCT01315236) for NTM.…”

Professor Pangloss and the Pangenome: Does Staphylococcus aureus Have the Best of All Possible Worlds?

“…Finally, the authors suggest that new antimicrobial agents might be designed to reduce the virulence of the organism without exerting selective pressure for resistance -such agents have been proposed as useful "antibiotic adjuvants" (17).…”